NRX Pharmaceuticals, Inc. Deferred Other Tax Expense (Benefit)
NRX Pharmaceuticals, Inc. (NRXP) reported Deferred Other Tax Expense (Benefit) of $105.56 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-05-14.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredOtherTaxExpenseBenefit · last filed 2021-05-14
- NRX Pharmaceuticals, Inc. deferred other tax expense (benefit) for the quarter ending 2017-12-31 was $22.06K.
- NRX Pharmaceuticals, Inc. deferred other tax expense (benefit) for fiscal 2020 was $105.56K.
- NRX Pharmaceuticals, Inc. deferred other tax expense (benefit) for fiscal 2019 was -$21.06K.
- NRX Pharmaceuticals, Inc. deferred other tax expense (benefit) for fiscal 2018 was -$995.00.
| Period end | Deferred Other Tax Expense (Benefit) 3 month | Deferred Other Tax Expense (Benefit) 12 month |
|---|---|---|
| 2020-12-31 | $105.56K 10-K/A · filed 2021-05-14 | |
| 2019-12-31 | -$21.06K 10-K/A · filed 2021-05-14 | |
| 2018-12-31 | -$995.00 10-K · filed 2020-03-30 | |
| 2017-12-31 | $22.06K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |